Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Immunomodulatory interventions vs placebo Allergic reactions · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Cognitive effects · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Quality of life · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (total hip/femoral neck) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR BMD Z score (wrist) Â · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of fractures · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mobility · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects of treatment · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo BMD Z score (wrist) · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Incidence of fractures · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Mobility · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (lumbar spine) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Quality of life · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Adverse effects of treatment · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Incidence of fractures · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Mobility · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Quality of life · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Adverse effects of treatment · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo BMD Z score (total hip/femoral neck) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (wrist) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo BMD Z score (wrist) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Incidence of fractures · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Mobility · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Adverse effects of treatment · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment Mobility · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Device‐modified trabeculectomy vs standard trabeculectomy Postoperative mean visual field change at 1 year · people with glaucoma Device‐modified trabeculectomy for glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Device‐modified trabeculectomy vs standard trabeculectomy Quality of life at 1 year · people with glaucoma Device‐modified trabeculectomy for glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Physical exercise vs no treatment Incidence of venous leg ulcer · people with non‐ulcerated chronic venous insufficiency Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Shift duration of no more than 16 hours vs shift duration of 24 to 28 hours Other secondary outcomes (number of staff; overtime; staff costs) · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Shorter shifts (8 or 10 hours) vs shifts lasting 2 to 3 hours longer Other secondary outcomes (number of staff; number of hours worked; staff costs) · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ More compressed schedules vs less compressed schedules Sleepiness during shifts · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ More compressed schedules vs less compressed schedules Secondary outcomes (number of staff; number of hours worked; overtime; staff costs) · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Forward rotation vs backward rotation Secondary outcomes (number of staff; number of hours worked; overtime; staff costs) · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Faster rotation vs slower rotation Secondary outcomes (number of staff; number of hours worked; overtime; staff costs) · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Shift duration of no more than 16 hours vs shift duration of 24 to 28 hours Sleep quality off‐shift · shift workers Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Deaths due to vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Disability due to vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in quality of life · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral factor Xa inhibitors vs conventional anticoagulation Health‐related quality of life · people with a pulmonary embolism, confirmed by standard imaging techniques Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation All‐cause mortality · people with a pulmonary embolism, confirmed by standard imaging techniques Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation Health‐related quality of life · people with a pulmonary embolism, confirmed by standard imaging techniques Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: cavosonstat vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: cavosonstat vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Quality of life ‐ total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Quality of life ‐ total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Quality of life: total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Quality of life: respiratory domain · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |